E2F1 can increase ccRCC cell proliferation and epithelial–mesenchymal transition (EMT) and promote tumor progression of a mouse xenograft model by inhibiting SREBP-1-mediated aberrant lipid metabolism (128). This evidence concerns the gene E2F1 and nonpapillary renal cell carcinoma.